DIVISLAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 50/100 — Quality 83 · Valuation 11 · Growth 43 · Momentum 53
| Share price | ₹7,318.00 |
| Market cap | ₹1.70 lakh Cr |
| P/E ratio | 68.5 |
| P/B ratio | 11.0 |
| ROE | 16.3% |
| ROCE | 18.9% |
| Dividend yield | 0.47% |
| Book value | ₹580.95 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹10,560 Cr | ₹2,568 Cr | 33.0% |
| 2025 | ₹9,360 Cr | ₹2,191 Cr | 32.0% |
| 2024 | ₹7,845 Cr | ₹1,600 Cr | 28.0% |
| 2023 | ₹7,768 Cr | ₹1,823 Cr | 31.0% |
| 2022 | ₹8,960 Cr | ₹2,960 Cr | 43.0% |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Re